Epigenetic connections between autoimmune disorders and haematological malignancies

Trends in Immunology

Volumn 29, Issue 12, 2008, Pages 616-623

  Javierre, Biola M ^a,b   Esteller, Manel ^a   Ballestar, Esteban ^a,b  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 5 METHYLCYTOSINE; AZACITIDINE; CD40 LIGAND; CD70 ANTIGEN; DEATH RECEPTOR 3; DNA; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3B; DNA METHYLTRANSFERASE INHIBITOR; GAMMA INTERFERON; HISTONE DEACETYLASE INHIBITOR; HYDRALAZINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; PROCAINAMIDE; TRANSCRIPTION FACTOR; TRICHOSTATIN A; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CD4+ T LYMPHOCYTE; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CHROMOSOMAL INSTABILITY; CLINICAL TRIAL; DISEASE ASSOCIATION; DNA METHYLATION; EPIGENETICS; FOOD AND DRUG ADMINISTRATION; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC DISORDER; HEMATOLOGIC MALIGNANCY; HUMAN; MEDICAL RESEARCH; MOTONEURON; MYELODYSPLASTIC SYNDROME; REVIEW; RHEUMATOID ARTHRITIS; STEM CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; T CELL LEUKEMIA; T CELL LYMPHOMA; T LYMPHOCYTE;

ANIMALS; AUTOIMMUNE DISEASES; CELL DIFFERENTIATION; EPIGENESIS, GENETIC; HEMATOLOGIC NEOPLASMS; HUMANS; T-LYMPHOCYTES; TRANSCRIPTION FACTORS;

EID: 56249113842     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2008.08.008     Document Type: Review

References (69)

1. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 8 (2007) 286-298
2. Fraga M.F., et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 10604-10609
3. Goodnow C.C. Multistep pathogenesis of autoimmune diseases. Cell 130 (2007) 25-35
4. Hansen A., et al. B-cell lymphoproliferation in chronic inflammatory rheumatic diseases. Nat. Clin. Pract. Rheumatol. 3 (2007) 561-569
5. Hansen R.S., et al. The DNMT3B DNA methyltransferase gene is mutated in the ICF immunodeficiency syndrome. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 14412-14417
6. Yamanouchi J., et al. Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat. Genet. 39 (2007) 329-337
7. Doi Y., et al. Orphan nuclear receptor NR4A2 expressed in T cells from multiple sclerosis mediates production of inflammatory cytokines. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 8381-8386
8. Richardson B., et al. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 33 (1990) 1665-1673
9. Wilson A.S., et al. DNA hypomethylation and human diseases. Biochim. Biophys. Acta 1775 (2007) 138-162
10. Wahlfors J., et al. Genomic hypomethylation in human chronic lymphocytic leukemia. Blood 80 (1992) 2074-2080
11. Roman-Gomez J., et al. Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene 24 (2005) 7213-7223
12. Gaudet F., et al. Induction of tumors in mice by genomic hypomethylation. Science 300 (2003) 489-492
13. Kondo T., et al. Whole-genome methylation scan in ICF syndrome: hypomethylation of non-satellite DNA repeats D4Z4 and NBL2. Hum. Mol. Genet. 9 (2000) 597-604
14. Gibbons R.J., et al. Mutations in ATRX, encoding a SWI/SNF-like protein, cause diverse changes in the pattern of DNA methylation. Nat. Genet. 24 (2000) 368-371
15. + lupus T cells. J. Immunol. 172 (2004) 3652-3661
16. Lu Q., et al. Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs. J. Immunol. 174 (2005) 6212-6219
17. Lu Q., et al. Demethylation of ITGAL (CD11a) regulatory sequences in systemic lupus erythematosus. Arthritis Rheum. 46 (2002) 1282-1291
18. Lu Q., et al. Demethylation of CD40LG on the inactive X in T cells from women with lupus. J. Immunol. 179 (2007) 6352-6358
19. Takami N., et al. Hypermethylated promoter region of DR3, the death receptor 3 gene, in rheumatoid arthritis synovial cells. Arthritis Rheum. 54 (2006) 779-787
20. Harhaj N.S., et al. Deregulated expression of CD40 ligand in HTLV-I infection: distinct mechanisms of downregulation in HTLV-I-transformed cell lines and ATL patients. Virology 362 (2007) 99-108
21. Ortmann C.A., et al. Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region. Nucleic Acids Res. 33 (2005) 6895-6905
22. Shivapurkar N., et al. Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int. J. Cancer 109 (2004) 786-792
23. Richardson B. Effect of an inhibitor of DNA methylation on T cells. II. 5-Azacytidine induces self-reactivity in antigen-specific T4+ cells. Hum. Immunol. 17 (1986) 456-470
24. Scheinbart L.S., et al. Procainamide inhibits DNA methyltransferase in a human T cell line. J. Rheumatol. 18 (1991) 530-534
25. Deng C., et al. Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Arthritis Rheum. 48 (2003) 746-756
26. + T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. J. Clin. Invest. 92 (1993) 38-53
27. Mishra N., et al. Trichostatin A reverses skewed expression of CD154, interleukin-10, and interferon-γ gene and protein expression in lupus T cells. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 2628-2633
28. Cozen W., et al. Interleukin-2, interleukin-12, and interferon-γ levels and risk of young adult Hodgkin lymphoma. Blood 111 (2008) 3377-3382
29. Takeuchi T., et al. Upregulated expression and function of integrin adhesive receptors in systemic lupus erythematosus patients with vasculitis. J. Clin. Invest. 92 (1993) 3008-3016
30. Yung R., et al. Mechanisms of drug-induced lupus. II. T cells overexpressing lymphocyte function-associated antigen 1 become autoreactive and cause a lupus-like disease in syngeneic mice. J. Clin. Invest. 97 (1996) 2866-2871
31. Robillard N., et al. Phenotypic characterization of the human myeloma cell growth fraction. Blood 105 (2005) 4845-4848
32. Puig-Kröger A., et al. RUNX/AML and C/EBP factors regulate CD11a integrin expression in myeloid cells through overlapping regulatory elements. Blood 102 (2003) 3252-3261
33. Barreto G., et al. Gadd45a promotes epigenetic gene activation by repair-mediated DNA demethylation. Nature 445 (2007) 671-675
34. Salvador J.M., et al. Mice lacking the p53-effector gene Gadd45a develop a lupus-like syndrome. Immunity 16 (2002) 499-508
35. Finnish-German APECED Consortium. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat. Genet. 17 (1997) 399-403
36. Org T., et al. The autoimmune regulator PHD finger binds to non-methylated histone H3K4 to activate gene expression. EMBO Rep. 9 (2008) 370-376
37. Hässler S., et al. Aire-deficient mice develop hematopoetic irregularities and marginal zone B-cell lymphoma. Blood 108 (2006) 1941-1948
38. Yoo C.B., and Jones P.A. Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discov. 5 (2006) 37-50
39. Laird P.W., et al. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 81 (1995) 197-205
40. Silverman L.R., et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 7 Suppl. 1 (1993) 21-29
41. Cheng J.C., et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J. Natl. Cancer Inst. 95 (2003) 399-409
42. Kaminskas E., et al., FDA. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin. Cancer. Res. 11 (2005) 3604-3608
43. Fenaux P. Inhibitors of DNA methylation: beyond myelodysplastic syndromes. Nat. Clin. Pract. Oncol. 2 Suppl. 1 (2005) S36-S44
44. Yoshida M., et al. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 265 (1990) 17174-17179
45. Mann B.S., et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12 (2007) 1247-1252
46. Garcia-Manero G., et al. Phase I study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced leukemias and myelodysplastic syndromes. Blood 111 (2007) 1060-1066
47. Brogdon J.L., et al. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 109 (2007) 1123-1130
48. Mishra N., et al. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J. Clin. Invest. 111 (2003) 539-552
49. Reilly C.M., et al. Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. J. Immunol. 173 (2004) 4171-4178
50. Ryu H., et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J. Neurochem. 93 (2005) 1087-1098
51. Lin H.S., et al. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br. J. Pharmacol. 150 (2007) 862-872
52. Greiner D., et al. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. Nat. Chem. Biol. 1 (2005) 143-145
53. Huang Y., et al. Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 8023-8028
54. Bruniquel D., and Schwartz R.H. Selective, stable demethylation of the interleukin-2 gene enhances transcription by an active process. Nat. Immunol. 4 (2003) 235-240
55. + conventional T cells. Eur. J. Immunol. 37 (2007) 2378-2389
56. International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN), Harley J.B., et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat. Genet. 40 (2008) 204-210
57. Ueda H., et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423 (2003) 506-511
58. Baechler E.C., et al. Gene expression profiling in human autoimmunity. Immunol. Rev. 210 (2006) 120-137
59. Feinberg A.P., et al. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301 (1983) 89-92
60. Jones P.A., and Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3 (2002) 415-428
61. Costello J.F., et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat. Genet. 24 (2000) 132-138
62. Esteller M., et al. Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J. Natl. Cancer Inst. 94 (2002) 26-32
63. Herman J.G., et al. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res. 56 (1996) 722-727
64. Ropero S., et al. Epigenetic loss of the familial tumor-suppressor gene exostosin-1 (EXT1) disrupts heparan sulfate synthesis in cancer cells. Hum. Mol. Genet. 13 (2004) 2753-2765
65. Weber M., et al. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat. Genet. 37 (2005) 853-862
66. Bibikova M., et al. High-throughput DNA methylation profiling using universal bead arrays. Genome Res. 16 (2006) 383-393
67. Ballestar E., et al. Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J. 22 (2003) 6335-6345
68. Fraga M.F., et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 37 (2005) 391-400
69. Falini B., and Mason D.Y. Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. Blood 99 (2002) 409-426